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Abstract
Background: Global views emphasize the need for early; effective intervention against the atherogenic
dyslipidemia associated with type 2 diabetes and metabolic syndrome to reduce the risk of premature
cardiovascular diseases. Our aim was to determine the clinical practices and compliance among dyslipidemia with
type II diabetes and hypertension in multiracial society.
Method(s): Study was carried out in out-patient department of General hospital Penang over a period of ten
months (Jan - Oct 2008). Study reflects the retrospective data collection covering a period of three years from Jan
2005 - Dec 2007. Universal sampling technique was used to select all the patients’ undergone treatment for
diabetes type II and dyslipidemia. All the concerned approvals were obtained from Clinical research Committee
(CRC). Data was analyzed by using SPSS 15®.
Result(s): A total of 501 diabetes type 2 patients with dyslipidemia were identified in this study. The demographic
data showed that 55.9% (n = 280) were female patients and 44.1% (n = 221) were males. Patients on combination
therapy of metformin with other antidiabetic agent were 79%, while 21% were on monotherapy. Lovastatin was
received as monotherapy in 83% of study population, while only 17% were on combination with gemfibrozil. Means
of FPG and lipid profile were reduced from the initial (2005) to the latest level (2007) significantly (p < 0.001). Only
0.89% decrease in mean weight with S.D 13.1 as compared to initial S.D 12.8 after three years of Cohort. While in
description 35.2% representatives gain weight with majority of males (71.5%), 52.3% with weight loss of 1-3 pounds
majority (69.3%) with female respondents and rest 12.4% remains with same weight with mix gender distribution.
Conclusion: Metformin and lovastatin use among patients of type 2 diabetes and dyslipidemia is significantly
improved the clinical outcomes. No significant association of metformin or lovastatin is found against the
hypertension. Metformin and calcium channel blocker combination therapy was found to be the best choice in the
co-treatment of diabetes and hypertension.
Introduction
Metformin is the only oral antidiabetic agent proven to
reduce diabetes-related and total mortality in obese type
2 diabetes [1]. It has now been recommended as an
agent of choice in the treatment of type 2 diabetes
regardless of obesity [2]. Its predecessor, phenformin,
was abandoned due to fatal cases of lactic acidosis. The
use of metformin, with adherence to the contraindica-
tions and warnings, confirmed its safety in both post-
marketing surveillance studies [3,4] and several clinical
studies [5,6], where there was no excess risk of lactic
acid associated with its use, compared to those not tak-
ing any agent. In usual practice, metformin has been
widely prescribed for diabetic patients with a known
contraindicated condition, but, apparently, no lactic
acidosis cases were observed [7,8]. In fact, metformin
use was associated with fewer deaths or hospitalizations
in diabetes with heart failure [9,10]. On the other hand,
cases of metformin-associated lactic acidosis continued
to be reported sporadically [11-16]; concerns over the
risk thus remain existence. * Correspondence: wasifgillani@gmail.com
3Dept of Clinical Pharmacy, University Sains Malaysia
Full list of author information is available at the end of the article
Zaki et al. International Archives of Medicine 2010, 3:34
http://www.intarchmed.com/content/3/1/34
© 2010 Zaki et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Although the causes of increased cardiovascular risks
in both type 2 diabetes and metabolic syndrome are
multifactorial, an atherogenic lipid profile characterized
by elevated triglycerides and low levels of high-density
lipoprotein (HDL) cholesterol are few major modifiable
factor contributing progressively in cardiovascular risk
[17]. Level of low-density lipoprotein (LDL) cholesterol
typically is not elevated and in fact may even be below
average. Although the size of the LDL particle is lower
than average with the depletion of its cholesterol con-
tent, dense LDL does not contribute independently to
the risk of CVD and is simply a marker for high levels
of triglycerides and apolipoprotein B [18-20]. Thus be
notable that the development of insulin resistance, dysli-
pidemia, and hypertension lead to the onset of overt gly-
cemia and diabetes. During the latent phase before the
clinical diagnosis of diabetes usually between 5-10 years,
both macrovascular and microvascular complications
were developed [21]. As a result, up to 50% of patients
already have clinical evidence of macrovascular compli-
cations, and about 20% have microvascular complica-
tions at the time of diagnosis [22]. These findings
emphasize the need for early; effective intervention
against the atherogenic dyslipidemia associated with
type 2 diabetes and metabolic syndrome to reduce the
risk of premature CVD.
This study was aimed to characterize the clinical evi-
dences in the use of hypoglycemic agents with Dyslipi-
demic drugs, in term to monitor laboratory parameters
of Diabetes type II and Dyslipidemia. We assumed that
both principal therapies (Metformin & Lovastatin) are
significantly improving thec o r ec l i n i c a ls y m p t o m s .
Study also intended to identify the best combination of
hypoglycemic agents with antihypertensive medication
to control hypertension with definitive diabetic control.
Method(s)
A three years retrospective cross-sectional study was
planned to achieve the above-mentioned objectives of
the study. Study was carried out in out-patient depart-
ment of General hospital Penang over a period of ten
months (Jan - Oct 2008). During the data collection per-
iod, study deemed to cover three years cohort analyses
which include 2005, 2006, 2007. Study population was
targeted on the basis of type II diabetes with dyslipide-
mia and hypertension. Then the identified cohort of
patients was analyzed against the respective monitoring
parameters to identify the compliance and therapeutic
effectiveness during a period of 3 years.
We took the continuous form of data for each monitor-
ing parameter and compare and contrast against the mean
and standard deviations against the normal range of stan-
dard hospital setting. All of the monitoring parameters
were divided into two datasets’, one includes the baseline
reading on the initiation of the therapy and other was the
last recorded value with the same therapy. If the therapy
was changed from mono to combine therapy then the last
lab values will be considered as the baseline value of com-
bined-drug therapy and vice-versa. Patients’ medication
profile and laboratory tests for glucose and lipids were the
prime monitoring parameters in this study. The study is
certified with the approval of Clinical Research Committee
(CRC) as all the ethical requirements were fulfilled during
the study period.
Data obtained were analyzed by using the Statistical
Package of Social Sciences (SPSS) version 15®, Chi-square,
paired and independent t-tests as well as univariate analy-
sis of variance (ANOVA) have been used to compare
results. The level of significance was 0.05 with the confi-
dence interval of 95%. All the results and findings were
then illustrated in discussion section. We intend to find
out the argument issues in this study to be benefited
against the clinical practice.
Result(s)
A total of all only 501 diabetes type 2 patients with dysli-
pidemia and hypertension were identified in this study by
employing universal sampling. The demographic data
showed that 55.9% (n = 280) were female patients and
44.1% (n = 221) were male patients. According to racial
distribution, Chinese constituted 41.7% of the study
population, Malay 34.3% and Indians 24%. The mean age
was 62.2 ± 9.2 years. About 56.1% of patients were more
and equal than 60 years old range, while 43.9% were in
the less or equal range of 59 years. Lifestyle and social
habits data demonstrated 86.2% non-smokers, 74.1% with
uncontrolled diet and 78.4% on bad exercise. Patients on
combination therapy of metformin with other antidia-
betic agent were 79%, while 21% were on monotherapy.
Lovastatin was received as monotherapy in 83% of
study population, while only 17% were on combination
with gemfibrozil. Means of fasting plasma glucose (FPG)
and lipid profile were reduced from the initial (2005) to
the latest level (2007) significantly (p < 0.001) [23].
Progressive data analysis showed that 0.89% decrease
in mean weight with S.D 13.1 as compared to initial S.D
12.8 over three years of time frame. While in description
35.2% representatives gain weight with majority of males
(71.5%), 52.3% with weight loss of 1-3 pounds majority
(69.3%) with female respondents and rest 12.4% remains
with same weight with mix gender distribution. Fasting
plasma glucose as a therapeutic monitoring of antidia-
betic drug showed significant (p < 0.001) change of
mean S.D value; towards low in the end of cohort as
comparison initial base line values, but HbA1c value
showed inconsistent results towards high mean S.D
value in end of cohort with initial base line data. In con-
trast to metformin, lovastatin showed vice-versa better
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High-density Lipoproteins (table 1).
Significant ineffective therapeutic outcomes were
observed with uncontrolled FBS among combination of
other antidiabetic drugs with metformin with p < 0.001
(table 2). Similarly better therapeutic compliance with
monotherapy of Lovastatin was observed against the
monitoring parameter of lowering LDL (89.9%) with
increasing in HDL (94.7%) levels. While hypertension
was significantly (p < 0.001) found among both mono-
therapy (77.9%) and combination therapy (76.5%) group
(table 3). Finally our findings reflected that both metfor-
min and lovastatin showed less medical complications
with combination therapy or substitution with other
therapeutic agents (table 4).
Discussion
Patients with diabetes mellitus have a 2- to 4-fold
increased risk of cardiovascular, peripheral vascular and
cerebrovascular disease, which are the leading causes of
morbidity and mortality in this population. Few epide-
miological studies have shown an association between
diabetic dyslipidemia, which is characterized by hypertri-
glyceridemia; low levels of high-density lipoprotein cho-
lesterol; postprandial lipemia; and small, dense low-
density lipoprotein cholesterol (LDL-C) particles - and
the occurrence of cardiovascular disease. Metformin
with thiazolidinedione/statins can be useful for the treat-
ment of diabetic dyslipidemia [24].
Metformin works by increasing the number of muscle
and adipocyte (fat cell) insulin receptors and the attrac-
tion for the receptor. It does not increase insulin secre-
tion, it only increases insulin sensitivity. Therefore,
metformin is not associated with causing hypoglycemia.
This activity reduces insulin levels by increasing the sen-
sitivity of peripheral tissues to the effects of insulin by
rejuvenating the response, and restoring glucose and
insulin to younger physiological levels that may cause
weight loss and most certainly a decrease in the body’s
total fat content [24-29]. The moderate pattern of
decrease in HbA 1c during the mid phase of study has
been shown to decrease total cholesterol and triglycer-
ides, with significant change has been observed in HDL
and LDL cholesterol [30].
It is often that patients with type II diabetes present
with a cluster of cardiovascular risk factors like visceral
Table 1 Monitoring parameters in cohort of study
Parameters Mean (SD) N (%)
Weight 501
Initial weight 66.7 (12.8)
Last weight 66.1 (13.1)
Weight Change
Increase - 177 (35.3%)
Decrease - 262 (52.3%)
No change - 62 (12.4%)
Fasting Plasma Glucose 501
Initial 22.7 (116.3)
During 8.4 (2.4)
Last 8.2 (2.4)
HbA1c test
Initial 7.9 (1.8) 123 (24.6)
During 7.9 (1.6) 215 (42.9)
Last 8.2 (1.9) 194 (38.7)
Total Cholesterol 501
Initial 63.5 (232.1)
During 63.4 (152.0)
Last 25.1 (139.1)
Triglycerides 501
Initial 65.8 (243.9)
During 27.8 (158.6)
Last 19.7 (132.6)
Low-density Lipoprotein 501
Initial 101.1 (295.9)
During 45.3 (199.7)
Last 39.1 (185.5)
High-density Lipoprotein 501
Initial 67.1 (247.7)
During 31.2 (170.2)
Last 21.2 (139.7)
Alkaline Phosphatase-ALP 501
Initial 158.3 (262.1)
During 124.4 (197.8)
Last 104.3 (159.4)
Alanine Transferase - ALT 501
Initial 111.3 (276.1)
During 70.1 (204.4)
Last 50.0 (155.7)
Table 2 Medication outcome with Metformin use
Parameters (N = 501) Metformin N(%)
Monotherapy Combination c
2 value
Monitoring
Fasting Plasma glucose 105 (20.9) 396 (79.1) 0.001
Controlled 44 (41.9) 92 (23.2)
Uncontrolled 61 (58.1) 304 (76.8)
Adverse Effects
Nausea - 1 (0.3)
Bloating - 4 (1.0)
Diarrhea 1 (0.9) 3 (0.8)
Headache - 1 (0.3)
Weakness - 4 (1.0)
No adverse effects 104 (99.1) 383 (96.6) 0.023
Hypertension complication
YES 86 (81.9) 303 (76.5) 0.001
NO 19 (18.1) 93 (23.5)
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density lipoprotein (HDL) cholesterol levels, and hypofi-
brinolysis, all of which form insulin resistance and
potentially contribute to increased cardiovascular risk
[30]. In the United Kingdom Prospective Diabetes
Study, metformin was the only medication that reduced
diabetes related deaths, heart attacks and strokes
[15-20,31,32]. On the contrary, a few reports have docu-
mented a lack of effect of metformin on blood pressure
[7-9,33]. Our study findings reflects the same identity of
increase hypertension among both mono or combine
therapy with metformin. So it is reviewed that long-
term infusion with apparently nontoxic doses of metfor-
min attenuates hypertension and decreases the hypoten-
sive responses to ganglionic blockade in salt-induced
hypertensive response (SHR), suggesting a centrally eli-
cited sympathoinhibitory action [34].
A decrease in plasminogen activator inhibitor was
most associated with the body weigh loss in subjects
[31,35], but in our study no significant decrease in
weight is observed whilst a significant pattern of weight
gain is found. Probably these results suggested the non-
exercise behavior with poor diet. In the observation of
daily clinical practice, antidiabetic drug initiation for
patients is sometimes delayed due to the potential risk
of hypoglycemia, the need to educate patients on the
use of antidiabetic drugs, the need to increase glucose
control and concern over weight gain [11].
The multi-preventive effects of metformin on type II
diabetes and evolving cardiovascular complications include
a decrease in total cholesterol and low density cholesterol
(LDL), free fatty acids, tissue plasminogen activator anti-
gen and insulin levels when patients present with symp-
toms of hypertension, dyslipidemia, visceral obesity or
hyperglycemia [31] in contrast to such reviews we find
unusual high percentage of hypertension even with or
without glycemic control and decrease in LDL and total
cholesterol. Probably reason lies in two bare facts; first
possibility suggest that due to increase of triglycerides
(>2.25 mmol/L) with low LDL and HDL ratio [23-30] and
second possibility is the weight gain with no-exercise
behavior and poor diet control [11-13,17,24,31-34].
Long term use of metformin may cause malabsorption
of vitamin B12 [21,25-27,31]. Because of the depletion
of B12, supplementation is recommended [25-27].
When a person begins to take metformin, they may
experience some nausea and vomiting, stomach pain,
bloating and diarrhea [15,27]. Studies were conducted in
the past that describe the pattern of oral antidiabetic
and insulin use. These provide data on the level of glu-
cose control achieved with each of these treatments,
mono or combined, at different stages of the disease,
the development of complications associated with DM2,
the duration of therapy for each defined treatment
Table 4 Complications association with combination
regimen among Cohort
Regimen design Complications
N/Total. (%)
c
2 value ǂ
Metformin (monotherapy) 94/105. (89.5) 0.001
Lovastatin (monotherapy) 364/416. (87.5) 0.001
Sulfonlyurea 336/384. (87.5) 0.023
Insulin 70/73. (95.9) 0.001
Insulin & Oral hyperglycemic
agent
61/64. (95.3) 0.001
Metformin & Diuretics 95/95. (100.0) 0.000
Metformin & Calcium Channel
block
17/17. (100.0) 0.000
Metformin & Digoxin 2/2. (100.0) 0.000
Metformin & corticosteroid 9/9. (100.0) 0.000
Metformin & Nefidine 87/87. (100.0) 0.000
Lovastatin & Gemfibrozil 17/17. (100.0) 0.000
Lovastatin & other
combinations
61/68. (89.7) 0.018
ǂ all the variables were in 2 × 2 type (as. Metformin = monoXcomb.etc),
Similarly complications section is dictomise into (yes & no). Sig. value is taken
on individual analysis latter compressed in this table.
Table 3 Medication outcome with Lovastatin use
Lovastatin N(%)
Parameters (N = 501) Monotherapy Combination c
2
value
Monitoing
Total cholesterol 416 (83.0) 85 (17.0) 0.001
High 40 (9.6) 12 (14.1)
Normal 376 (90.4) 73 (85.9) 0.001
Triglycerides
High 75 (18.0) 34 (40.0) 0.001
Normal 341 (82.0) 51 (60.0)
Low-density
Lipoprotein
High 42 (10.1) 10 (11.8) 0.025
Normal 374 (89.9) 73 (88.2)
High-Density
Lipoprotein
Low 22 (5.3) 5 (5.9) 0.031
Normal 394 (94.7) 80 (94.1)
ALT
High 34 (8.2) 10 (11.8) 0.16
Normal 382 (91.8) 75 (88.2)
ALP
High 46 (11.0) 5 (5.9) 0.54
Normal 370 (88.9) 80 (94.1)
Hypertension
YES 324 (77.9) 65 (76.5)
NO 92 (22.1) 20 (23.5) 0.001
Adverse Effects
YES 14 (3.4) 9 (10.6)
NO 402 (96.6) 76 (89.4) 0.045
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was changed [35-38].
Conclusion
Metformin and lovastatin use among patients of type 2
diabetes and dyslipidemia is significantly improved the
clinical outcomes. No significant association of metfor-
min or lovastatin is found against the hypertension.
Metformin and calcium channel blocker combination
therapy was found to be the best choice in the co-treat-
ment of diabetes and hypertension.
Hypertension is significantly found in both controlled
and normal total cholesterol reading patients. This may
reflects the attitude that lowering the FBS and total cho-
lesterol can control hypertension, but for instance the
hypertension among such patients have some inevitable
cause to control.
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